Trials / Conditions / Myasthenia Gravis, Generalized

Myasthenia Gravis, Generalized

29 registered clinical trials studyying Myasthenia Gravis, Generalized — 15 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis NCT07501702	Vertex Pharmaceuticals Incorporated	Phase 2
Not Yet Recruiting	Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360 NCT07323316	Ad scientiam	N/A
Not Yet Recruiting	Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After NCT07226830	BioSensics	—
Not Yet Recruiting	Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis NCT07224386	BioSensics	—
Recruiting	Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With NCT07072988	Centre Hospitalier Universitaire de Nice	Phase 4
Recruiting	Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis NCT06909253	AstraZeneca	—
Not Yet Recruiting	The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis NCT06958939	Ting Chang, MD	Phase 1
Not Yet Recruiting	Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. NCT06485232	Xuanwu Hospital, Beijing	EARLY_Phase 1
Recruiting	Markers of Favorable Response to FcRn Inhibitors(INFORM) NCT06685055	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	—
Recruiting	Markers of Favorable Response to Complement Inhibitors Therapy NCT06455709	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	—
Active Not Recruiting	A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor NCT06298552	argenx	Phase 3
Active Not Recruiting	A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) NCT06282159	Dianthus Therapeutics	Phase 2
Recruiting	Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research NCT04806620	Brain Inflammation Collaborative	—
Unknown	Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis NCT05716035	Tang-Du Hospital	Phase 2 / Phase 3
Completed	Study of Telitacicept in Generalized Myasthenia Gravis NCT05737160	RemeGen Co., Ltd.	Phase 3
Recruiting	Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis NCT05067348	Tang-Du Hospital	Phase 2
Recruiting	Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) NCT05868837	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Phase 3
Recruiting	Predictors and Prognostic Factors of Myasthenia Gravis Outcome NCT05214612	Assiut University	—
Completed	Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study NCT04431895	Huashan Hospital	EARLY_Phase 1
Withdrawn	A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis NCT04224506	ProgenaBiome	—
Active Not Recruiting	Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) NCT04146051	Cartesian Therapeutics	Phase 2
Completed	Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis NCT04115293	Ra Pharmaceuticals, Inc.	Phase 3
Completed	A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Grav NCT03759366	Alexion Pharmaceuticals, Inc.	Phase 3
Withdrawn	A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis NCT03165435	CuraVac	Phase 2 / Phase 3
Completed	Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG NCT03304054	Catalyst Pharmaceuticals, Inc.	Phase 3
Completed	Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis NCT02565576	Novartis Pharmaceuticals	Phase 2
Completed	A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Grav NCT02473952	Grifols Therapeutics LLC	Phase 2
Recruiting	Myasthenia Gravis Foundation of America Global MG Patient Registry NCT06617741	Myasthenia Gravis Foundation of America	—
Completed	A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Sy NCT00683969	Hoffmann-La Roche	Phase 3